TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26303188
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablets (FBTs)
Study: 17308893
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg daily with oral etoposide starting at 50 mg every other day
Study: 17308893
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide alone (baseline pharmacokinetic studies)
Study: 17308893
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg daily with oral etoposide
Study: 12877651
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation with arachidonic acid (AA) at a dosage of 4 g/day for 8 weeks
Study: 11161542
Drug: GLY-GLN (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLY-GLN (500 ml glycyl-glutamine; 35 g GLN; 0.5 g/kg BW)
Study: 11161542
Drug: Control (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (1500 ml Vamin)
Study: 11161542
Drug: ALA-GLN (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-GLN (500 ml alanyl-glutamine; 35 g GLN; 0.5 g/kg BW)
Study: 9587049
Drug: Clovir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clovir (400 mg)
Study: 9587049
Drug: Zovirax (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zovirax (400 mg)
Study: 4629183
Drug: D.S.C.G.-isoprenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: D.S.C.G.-isoprenaline
Study: 4629183
Drug: D.S.C.G.
Approvals — FDA: no, EMA: no, PMDA: no
Description: D.S.C.G.
Study: 4629183
Drug: D.S.C.G.-isoprenaline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: D.S.C.G.-isoprenaline and D.S.C.G.
Study: 4629183
Drug: Full dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dosage
Study: 31821109
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy plus trastuzumab (CRxT)
Study: 31821109
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy alone (CRx)
Study: 25807902
Drug: Full-mouth therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth therapy (complete scaling and root planing in one stage within 24 h)
Study: 25807902
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (scaling and root planing performed by quadrant over a period of 4 weeks)
Study: 19697106
Drug: Oral dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosage form of tolterodine tartrate
Study: 14760340
Drug: Urapidil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (200 microg/kg intravenously, followed by 30 mg/d orally)
Study: 17402274
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg once daily
Study: 1997054
Drug: Temazepam 30
Normalized name: temazepam 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 30 mg in elixir formulation
Study: 1997054
Drug: Temazepam 30
Normalized name: temazepam 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 30 mg in capsule formulation
Study: 6519348
Drug: Nimesulide 200
Normalized name: nimesulide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 200 mg b.i.d.
Study: 29752593
Drug: Kallidinogenase (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kallidinogenase (150 units administered daily for 52 weeks)
Study: 20823433
Drug: Fluorouracil plus
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil plus folinic acid (20 mg/m² intravenous bolus injection followed by 425 mg/m² intravenous bolus injection given 1-5 days every 28 days)
Study: 20823433
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m² intravenous infusion once a week for 3 of every 4 weeks)
Study: 18166759
Drug: Epinephrine ampules
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine ampules labeled with mass concentration (1 mg in 1 mL)
Study: 18166759
Drug: Epinephrine ampules
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine ampules labeled with ratio (1 mL of a 1:1000 solution)
Study: 11154807
Drug: Single-day praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-day praziquantel therapy (n=14)
Study: 11154807
Drug: Non-treatment (n=12)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment (n=12)
Study: 11154807
Drug: Praziquantel treatment
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel treatment after non-treatment
Study: 1829091
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of long and short acting GnRH analogues (group II)
Study: 6673029
Drug: Pentoxifylline (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1,200 mg/day for 30 days)
Study: 31237645
Drug: P2Y12 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P2Y12 inhibitor monotherapy after 3 months of DAPT (n=1495)
Study: 31237645
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) for 12 months (n=1498)
Study: 27667369
Drug: NAVIGATE treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAVIGATE treatment (comprehensive, team-based treatment program with ≥5h of SEE services per week)
Study: 25097397
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of beta urogastrone (recombinant human epidermal growth factor) gel
Study: 23210239
Drug: Rebamipide tablets
Normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rebamipide tablets from Yuanlijian (test)
Study: 23210239
Drug: Rebamipide tablets
Normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rebamipide tablets from Otsuka (reference)
Study: 15868146
Drug: Trastuzumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly for up to 840 days)
Study: 17661792
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin re-uptake inhibitor (SSRI) treatment
Study: 30272528
Drug: 150 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 μg/day iodine
Study: 30272528
Drug: 300 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 μg/day iodine
Study: 25733331
Drug: Large doses
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large doses of ambroxol hydrochloride
Study: 25733331
Drug: Normal doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal doses of ambroxol hydrochloride
Study: 17032185
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (fentanyl plus propofol, midazolam plus propofol, fentanyl plus midazolam plus propofol)
Study: 10669283
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine 6.0 mg/kg
Study: 10669283
Drug: Rectal diazepam
Normalized name: diazepam Rectal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diazepam 0.5 mg/kg and diclofenac 12.5 mg
Study: 3177831
Drug: Midazolam (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.15 mg/kg) combined with Piritramid (0.1 mg/kg)
Study: 3177831
Drug: Thalamonal (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalamonal (0.04 ml/kg)
Study: 30676232
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care and daily activities (Control group).
Study: 29031658
Drug: Brimonidine 0.33%
Normalized name: Brimonidine 0.33% Topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine 0.33% topical gel
Study: 21166575
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy targeting normal glycosylated hemoglobin (HbA1c) levels, tight lipid control with fenofibrate and statin, aggressive blood pressure treatment with a systolic blood pressure goal of 120 mmHg
Study: 8737633
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 400 mg of buflomedil during 4 h of dialysis
Study: 8737633
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of buflomedil in six other patients maintained on intermittent hemodialysis (3 per week) for 4 weeks
Study: 31851170
Drug: 2% articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% articaine solution
Study: 10619812
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine solution
Study: 24525598
Drug: Icodextrin-based dialysis
Normalized name: Icodextrin Peritoneal Dialysis Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icodextrin-based dialysis solution (ICO group)
Study: 22889955
Drug: Raloxifene hydrochloride
Normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene hydrochloride (RLX) (60 mg/day) plus SOC (PegIFNα2a 180 μg/week and RBV 600‐1,000 mg/day)
Study: 22889955
Drug: SOC only
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC only (PegIFNα2a 180 μg/week and RBV 600‐1,000 mg/day)
Study: 20233275
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg vardenafil ODT on demand
Study: 16100448
Drug: Inhaled glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticoids (fluticasone propionate 1,000 microgram/day) for 4 weeks
Study: 10084469
Drug: Salmeterol powder
Normalized name: salmeterol Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol powder (50 microg) twice daily for 52 weeks
Study: 2202792
Drug: 10 U/mL
Normalized name: HEPARIN 10 U/ML PF LOCK FLUSH SYR 5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 U/mL heparin (H)
Study: 2202792
Drug: 10 U/mL
Normalized name: HEPARIN 10 U/ML PF LOCK FLUSH SYR 5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 U/mL heparin and 25 micrograms/mL vancomycin (H-V)
Study: 31201957
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil (KO) supplementation (5 g)
Study: 31201957
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation (5 g)
Study: 25869324
Drug: High-dose ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ibuprofen (HDI)
Study: 15284085
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen (0.625 mg per day)
Study: 15284085
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (100 microg per day)
Study: 8214918
Drug: 8% CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% CO2 inhalation
Study: 8214918
Drug: 2, 4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2, 4, 6% CO2 inhalation
Study: 31826183
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of caffeine (CAF)
Study: 31826183
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of cellulose as a placebo (PLA)
Study: 29791677
Drug: Monthly medical
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly medical visits with provision of insulin pens and strips for blood glucose measurement, including insulin pen, refills of Neutral Protamine Hagedorn and regular insulin, needles for the pen, blood glucose meter, and capillary blood glucose tests (three tests/day) for six months.
Study: 22333849
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (4 doses of 20 mg at 1-month intervals)
Study: 22333849
Drug: Nontreatment (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nontreatment (no medicine)
Study: 20102447
Drug: 4-mg silodosin
Normalized name: silodosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mg silodosin
Study: 18336918
Drug: CGT (Complicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGT (Complicated Grief Therapy)
Study: 15901743
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg IM ziprasidone
Study: 15901743
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg IM ziprasidone
Study: 15901743
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg IM ziprasidone
Study: 15901743
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg IV ziprasidone
Study: 15901743
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral ziprasidone
Study: 10637713
Drug: roxatidine 75
Normalized name: roxatidine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine 75 mg hs for 8 weeks
Study: 10637713
Drug: roxatidine 75
Normalized name: roxatidine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine 75 mg hs for 8 weeks + metronidazole 250 mg and amoxicillin 250 mg qid for 1 week on the 3rd week
Study: 10637713
Drug: Mylanta (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mylanta (20 ml qid for 8 weeks)
Study: 10637713
Drug: Mylanta (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mylanta (20 ml qid for 8 weeks) + metronidazole 250 mg and amoxicillin 250 mg qid for 1 week on the 3rd week
Study: 1822427
Drug: Day center
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day center treatment
Study: 1822427
Drug: Walk-in clinic
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walk-in clinic treatment
Study: 25233911
Drug: Additive solution-7
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additive solution-7 (AS-7)
Study: 25233911
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution AS-1
Study: 22981094
Drug: Submucosal 2
Normalized name: mepivacaine
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Submucosal 2 mL 100 mg tramadol injection (group T)
Study: 22981094
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (group P)
Study: 22635164
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg testosterone undecanoate (intramuscular injection at weeks 0, 6, 18, 30, and 42)
Study: 22635164
Drug: Placebo (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intramuscular injection at weeks 0, 6, 18, 30, and 42)
Study: 19135839
Drug: Contrast-enhanced ultrasound
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced ultrasound imaging (CEUS) with a dose of 2.4 mL of a second-generation contrast agent.
Study: 17690122
Drug: Prednisone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (30 mg.day(‐1))
Study: 16212139
Drug: Risedronate at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate at 5 mg/d
Study: 16212139
Drug: Risedronate at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate at 15 mg/d
Study: 16212139
Drug: Risedronate at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate at 35 mg once weekly
Study: 16212139
Drug: Risedronate at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate at 50 mg once weekly
Study: 19093930
Drug: Medicare Part
Normalized name: benzocaine / menthol Medicated Pad [Medicaine Sting]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicare Part D coverage for clopidogrel, proton pump inhibitors (PPIs), warfarin, and statins
Study: 19093930
Drug: Other study
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other study drug classes (warfarin, statins, benzodiazepines)
Study: 10823442
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg orally 1 hour before barium suspension
Study: 10823442
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg orally 1 hour before barium suspension
Study: 8542002
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (100,000 IU oral)
Study: 23510792
Drug: Rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal misoprostol (600 ?g)
Study: 23510792
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion (20 intravenous units)
Study: 15218330
Drug: benidipine (4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: benidipine (4-8 mg/day)
Study: 15218330
Drug: nifedipine CR
Normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine CR (20-40 mg/day)
Study: 11523124
Drug: Method 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method 1 (conventional procedure): oral magnesium citrate followed by glycerin enema.
Study: 11523124
Drug: Method 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method 2 (new procedure): oral magnesium citrate followed by oral picosulfate and bisacodyl suppository.
Study: 9748048
Drug: Gabapentin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (300 to 2,400 mg/d)
Study: 7820984
Drug: Intravenous clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clarithromycin infusion (1.5 mg/kg)
Study: 3273863
Drug: One antacid
Normalized name: Acid Gone Antacid
DrugBank: Magnesium carbonate (DB09481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One antacid tablet (experimental)
Study: 3273863
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of liquid antacid (commercial)
Study: 3273863
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of liquid antacid (commercial)
Study: 3273863
Drug: Two antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two antacid tablets (experimental)
Study: 26960538
Drug: Gadobutrol at
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadobutrol at the recommended dose (0.11 mmol/kg body weight)
Study: 26960538
Drug: Gadobutrol at
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadobutrol at the recommended dose
Study: 25775052
Drug: Bivalirudin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin with a post-PCI infusion (n=735)
Study: 25775052
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone (n=729)
Study: 25775052
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus tirofiban (n=730)
Study: 21558571
Drug: Slow Reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow Reduction (SR) - 0.7% weekly weight loss
Study: 21558571
Drug: Fast Reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast Reduction (FR) - 1.4% weekly weight loss
Study: 15648293
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (specific regimens not detailed)
Study: 15648293
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with radiotherapy (specific regimens not detailed)
Study: 7931477
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg twice daily by mouth for 1 year
Study: 7931477
Drug: Cyclophosphamide 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 60 mg/m2/d by mouth for 1 year, methotrexate 15 mg/m2 IV weekly for 1 year, fluorouracil (5‐FU) 400 mg/m2 IV weekly for 1 year, vincristine .625 mg/m2 IV weekly for the first 10 weeks, and prednisone during weeks 1 to 10 with doses decreasing from 30 mg/m2 to 2.5 mg/m2 (CMFVP)
Study: 7931477
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tamoxifen and CMFVP
Study: 26990920
Drug: Continuing medical
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing medical therapy
Study: 25672380
Drug: EMLA (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA (25 mg/g lidocaine and 25 mg/g prilocaine)
Study: 25672380
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% benzocaine
Study: 23995608
Drug: Otamixaban (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otamixaban (bolus of 0.080 mg/kg followed by an infusion of 0.140 mg/kg per hour)
Study: 16118546
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin plus eptifibatide
Study: 11231385
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam and intravenous meperidine
Study: 9513074
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from five-membered-ring agents (cimetidine, ranitidine, famotidine) to roxatidine in the treatment of five-membered-ring resistant ulcers.
Study: 9513074
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from roxatidine to five-membered-ring agents in the treatment of roxatidine-resistant ulcers.
Study: 8296753
Drug: Conventional antiarrhythmic
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antiarrhythmic drugs